Eli Lilly 's fourth-quarter results blew past Wall Street estimates on Wednesday, as key GLP-1 drugs, Mounjaro for diabetes and Zepbound to treat obesity, grew triple-digits — and there's still plenty ...

The stock has climbed in the triple digits over the past three years. Now, though, after Lilly stock's 200% increase over three years, you may be wondering if the growth story has fully played out or ...

Eli Lilly (LLY) Q4 revenue jumped 43% to $19.3B. Mounjaro sales surged 110% to $7.4B. Novo Nordisk (NVO) expects sales to decline 5% to 13% in 2026 due to pricing pressures and patent losses. Lilly’s ...

Eli Tomac was involved in a first-turn crash in Round 5 of the SuperMotocross World Championship at State Farm Stadium in Glendale, Arizona, and was slow to rise. After remounting his KTM in 22nd, he ...

Eli Lilly beat earnings soundly yesterday. Today, the stock is selling off on new competition from Hims & Hers Health. Earnings weren't the problem. Lilly beat analyst forecasts for $6.93 per share in ...

CNBC's Annika Kim Constantino reports on GLP-1 demand as well as Eli Lilly and Novo Nordisk's stock performance. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and ...

UPPER MACUNGIE TWP., Pa. — Pharmaceutical giant Eli Lilly and Company is building a manufacturing campus in the Lehigh Valley, a multi-billion-dollar project that promises to create hundreds of new ...

Demand for weight loss drugs is high, and analysts predict the market may reach nearly $100 billion in a few years. Eli Lilly dominates the GLP-1 market in the U.S. 10 stocks we like better than Eli ...

CNBC's Annika Kim Constantino reports on GLP-1 demand as well as Eli Lilly and Novo Nordisk's stock performance. How a $30 billion welfare program became a 'slush fund' for states Rock the Country ...

Eli Lilly’s stock closed 10.3% higher on Wednesday after the drug giant reported triple-digit growth of Zepbound and Mounjaro, its game-changing weight-loss and Type 2 diabetes drugs. That’s the third ...